Proliferative rate of neoplastic B-cells in B-CLPD patients according to the type of sample analyzed: bone marrow (BM), peripheral blood (PB) and lymph node (LN)
| Subtype of B-CLPD/ type of sample (no. of cases) . | Proliferative rate, % of S+G2/M cells . | P . |
|---|---|---|
| B-CLL | .003* | |
| BM (n=78) | 0.7 ± 1 | |
| PB (n=123) | 0.4 ± 0.4 | |
| LN (n=9) | 0.5 ± 0.5 | |
| SMZL | NS | |
| BM (n=7) | 1.7 ± 2.4 | |
| PB (n=9) | 0.5 ± 0.2 | |
| HCL | ||
| BM (n=2) | 1.7 ± 2.4 | |
| LN (n=5) | 0.5 ± 0.2 | |
| MALT | NS | |
| BM (n=15) | 1.4 ± 1.4 | |
| PB (n=4) | 0.7 ± 0.5 | |
| LN (n=1) | 4.6 | |
| MCL | .04† | |
| BM (n=15) | 2 ± 1.3 | |
| PB (n=16) | 2.4 ± 4.3 | |
| LN (n=8) | 7.7 ± 8 | |
| FL | NS | |
| BM (n=37) | 3 ± 2.5 | |
| PB (n=9) | 2.1 ± 2 | |
| LN (n=25) | 3 ± 2 | |
| BL | NS | |
| PB (n=8) | 15 ± 3.4 | |
| LN (n=11) | 26 ± 13 | |
| DLBCL | NS | |
| BM (n=4) | 12.6 ± 19 | |
| LN (n=15) | 14 ± 7 | |
| LPL/WM | NS | |
| BM (n=31) | 2 ± 2 | |
| PB (n=2) | 1.1 ± 1.3 | |
| LN (n=3) | 10.6 ± 16.7 |
| Subtype of B-CLPD/ type of sample (no. of cases) . | Proliferative rate, % of S+G2/M cells . | P . |
|---|---|---|
| B-CLL | .003* | |
| BM (n=78) | 0.7 ± 1 | |
| PB (n=123) | 0.4 ± 0.4 | |
| LN (n=9) | 0.5 ± 0.5 | |
| SMZL | NS | |
| BM (n=7) | 1.7 ± 2.4 | |
| PB (n=9) | 0.5 ± 0.2 | |
| HCL | ||
| BM (n=2) | 1.7 ± 2.4 | |
| LN (n=5) | 0.5 ± 0.2 | |
| MALT | NS | |
| BM (n=15) | 1.4 ± 1.4 | |
| PB (n=4) | 0.7 ± 0.5 | |
| LN (n=1) | 4.6 | |
| MCL | .04† | |
| BM (n=15) | 2 ± 1.3 | |
| PB (n=16) | 2.4 ± 4.3 | |
| LN (n=8) | 7.7 ± 8 | |
| FL | NS | |
| BM (n=37) | 3 ± 2.5 | |
| PB (n=9) | 2.1 ± 2 | |
| LN (n=25) | 3 ± 2 | |
| BL | NS | |
| PB (n=8) | 15 ± 3.4 | |
| LN (n=11) | 26 ± 13 | |
| DLBCL | NS | |
| BM (n=4) | 12.6 ± 19 | |
| LN (n=15) | 14 ± 7 | |
| LPL/WM | NS | |
| BM (n=31) | 2 ± 2 | |
| PB (n=2) | 1.1 ± 1.3 | |
| LN (n=3) | 10.6 ± 16.7 |
Results expressed as means plus or minus 1 standard deviation. P values provided correspond to comparisons indicated.
B-CLPD indicates B-cell chronic lymphoproliferative disorders; B-CLL, B-cell chronic lymphocytic leukemia; SMZL, splenic marginal zone B-cell lymphoma; NS, statistically not significantly different (P > .05); HCL, hairy cell leukemia; MCL, mantle-cell lymphoma; MALT, mucosa-associated lymphoid tissue lymphoma; FL, follicular lymphoma; BL, Burkitt lymphoma; DLBCL, diffuse large B-cell lymphoma; and; LPL/WM, lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.
BM versus PB samples.
LN versus BM and PB samples.